Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1D | P28221 | 8/20 | 0.43 |
| ▸ | HTR1B | P28222 | 8/20 | 0.43 |
| ▸ | HTR1F | P30939 | 8/20 | 0.43 |
| ▸ | PARP1 | P09874 | 2/20 | 0.37 |
| ▸ | QDPR | P09417 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | THPO | P40225 | 1/20 | 0.36 |
| ▸ | HTR1A | P08908 | 3/20 | 0.36 |
| ▸ | USP7 | Q93009 | 1/20 | 0.35 |
| ▸ | PLG | P00747 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15804625 | 0.80 | KDM4E (0.38) | — | |
| SCHEMBL17001810 | 0.79 | HTR1D (0.41) | HTR1DHTR1BHTR1FPARP1QDPR | |
| SCHEMBL14782547 | 0.78 | HTR2B (0.38) | PARP1 | |
| SCHEMBL16475544 | 0.76 | HTR1B (0.39) | HTR1DHTR1BHTR1FPARP1QDPR | |
| SCHEMBL17001833 | 0.76 | HTR1F (0.39) | HTR1DHTR1BHTR1FPARP1QDPR | |
| SCHEMBL20908874 | 0.74 | HTR1F (0.38) | HTR1DHTR1BHTR1FPARP1QDPR | |
| SCHEMBL14782658 | 0.73 | KDM4E (0.51) | — | |
| SCHEMBL5950395 | 0.73 | CHRNB2 (0.41) | PARP1 | |
| SCHEMBL15430113 | 0.73 | CHRNB2 (0.41) | PARP1 | |
| SCHEMBL22130567 | 0.73 | HTR1D (0.37) | HTR1DHTR1BHTR1FPARP1QDPR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160000785-A1 | Novel Imidazole Amines as Modulators of Kinase Activity | MERCK PATENT GMBH (DE) | 2016-01-07 | — | — | US | disclosed |
| US-9145392-B2 | Imidazole amines as modulators of kinase activity | MERCK PATENT GMBH (DE) | 2015-09-29 | — | — | US | disclosed |
| US-20140343029-A1 | Novel Imidazole Amines as Modulators of Kinase Activity | MERCK PATENT GMBH (DE) | 2014-11-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160000785-A1 | Novel Imidazole Amines as Modulators of Kinase Activity | MAP3K11, MAP3K20, MAP3K19 | HTR1D 3304/4885HTR1B 2247/4885HTR1F 2281/4885 |
| US-20140343029-A1 | Novel Imidazole Amines as Modulators of Kinase Activity | MAP3K11, MAP3K20, MAP3K19 | HTR1D 3304/4885HTR1B 2247/4885HTR1F 2281/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.